(1R,3S,5S)-6,6-Dimethylbicyclo[3.1.0]Hexan-3-Ol | 16613-81-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,3S,5S)-6,6-Dimethylbicyclo[3.1.0]Hexan-3-Ol
• 英文别名: 6,6-Dimethylbicyclo<3.1.0.>hexan-trans-3-ol；6,6-dimethylbicyclo[3.1.0]hexan-3-ol；(1 S,3S,5R)-6,6-dimethyl-bicyclo[3.1.0]hexan-3-ol；(1S,3S,5R)-6,6-dimethyl-bicyclo[3.1.0]hexan-3-ol；(1S,3S,5R)-6,6-dimethylbicyclo[3.1.0]hexan-3-ol；6,6-Dimethyl-trans-bicyclo(3,1,0)hexanol-(3)
• CAS: 16613-81-3
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: HUADUHNYPJBEBQ-POBXSPIYSA-N

物化性质

• 沸点：
  177.1±8.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  9.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.23
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  (1R,3S,5S)-6,6-Dimethylbicyclo[3.1.0]Hexan-3-Ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 以80%的产率得到6,6-dimethylbicyclo[3.1.0]hexan-3-one
  参考文献：
  名称：

  6,6-二甲基双环[3.1.0]己-3-酮的规模化合成

  摘要：

  开发了一种将工业级 (+)-3-carene 转化为 6,6-二甲基双环 [3.1.0] 己-3-one 的简单五步过程。需要一个稳健的过程来提供 6,6-二甲基双环 [3.1.0] 己-3-one、最小化色谱、减少过量的银盐并避免有毒的铬氧化剂。开发并证明了一种依赖结晶和蒸馏的简单且可扩展的工艺可生产数百克 6,6-二甲基双环 [3.1.0] 己烷-3-one。

  DOI：

  10.1055/s-0036-1588484
• 作为产物：
  描述：

  (-)-cis-3-trans-4-Dibromocarane 在 lithium aluminium tetrahydride 、 过氧化氢苯甲酰 、 silver(l) oxide 作用下， 生成 (1R,3S,5S)-6,6-Dimethylbicyclo[3.1.0]Hexan-3-Ol
  参考文献：
  名称：

  Lochynski, S.; Jarosz, B.; Walkowicz, M., Journal fur praktische Chemie (Leipzig 1954), 1988, vol. 330, # 2, p. 284 - 288

  摘要：

  DOI：

文献信息

• Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists
  申请人：Bolli Martin

  公开号：US20080194670A1

  公开（公告）日：2008-08-14

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  这项发明涉及新型噻吩衍生物，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫抑制剂。
• Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists
  申请人：Bolli Martin

  公开号：US20080318955A1

  公开（公告）日：2008-12-25

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  这项发明涉及新型噻吩衍生物，它们的制备以及它们作为药用活性化合物的用途。这些化合物特别作为免疫抑制剂。
• [EN] 4-CARBONYL SUBSTITUTED 1,1,2-TRIMETHYL-1A,4,5,5A-TETRAHYDRO-1H-4-AZA-CYCLOPROPA'A!PENTALENE DERIVATIVES AS AGONISTS FOR THE G-PROTEIN-COUPLED RECEPTOR S1P1/EDG1 AND IMMUNOSUPPRESSIVE AGENTS<br/>[FR] UTILISATION DE DERIVES DE 1,1,2-TRIMETHYL-1A,4,5,5A-TETRAHYDRO-1H-4-AZA-CYCLOPROPA[A]PENTALENE A SUBSTITUTION 4-CARBONYLE COMME AGONISTES DU RECEPTEUR COUPLE AUX PROTEINES G S1P1/EDG1 ET AGENTS IMMUNOSUPPRESSEURS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005123677A1

  公开（公告）日：2005-12-29

  The invention relates to novel pyrrole compounds of the formula (I) wherein A represents -CH2CH2-, -CH=CH-, or -NH-CH2; Ar represents phenyl; mono-, di-, or tri-substituted phenyl, wherein the substituents are independently selected from halogen, lower alkyl, lower alkoxy, hydroxy-lower alkyl, hydroxy-lower alkoxy, 1-glyceryl, 2-glyceryl, cycloalkyl, mono- or di-lower alkylamino, methylenedioxy, ethylenedioxy, trifluoromethyl and trifluoromethoxy; or unsubstituted mono- or di-substituted 2-, 3- or 4-pyridyl, wherein the substituents are independently selected from lower alkoxy and hydroxy-lower alkoxy. The present invention provides novel compounds of formulae (I), (II) and (III) that are agonists for the G protein-coupled receptor S1P1/EDG1 and have a powerful and long-lasting immunosuppressive effect which is achieved by reducing the number of cirulating and infiltrating T- and B-lymphocytes, whitout affecting their maturation, memory or expansion. The reduction of circulating T-/B-lymphocytes as a result of S1P1/EDG1 agonism, possibly in combination with the observed improvement of endothelial cell layer function associated with S1P1/EDG1 activation, makes such compounds useful to treat uncontrolled inflammatory disease and to improve vascular functionality.

  该发明涉及式(I)的新型吡咯化合物，其中A代表- -，-CH=CH-或-NH-CH2；Ar代表苯基；单取代、双取代或三取代苯基，其中取代基独立地选自卤素、低烷基、低烷氧基、羟基-低烷基、羟基-低烷氧基、1-甘油基、2-甘油基、环烷基、单取代或双取代的低烷基氨基、亚甲二氧基、乙二氧基、三氟甲基和三氟甲氧基；或未取代的单取代或双取代的2-、3-或4-吡啶基，其中取代基独立地选自低烷氧基和羟基-低烷氧基。本发明提供了式(I)、(II)和(III)的新型化合物，它们是G蛋白偶联受体S1P1/EDG1的激动剂，并具有强大且持久的免疫抑制作用，通过减少循环和浸润的T和B淋巴细胞的数量来实现，而不影响它们的成熟、记忆或扩张。由于S1P1/EDG1的激动作用导致循环T/B淋巴细胞的减少，可能与S1P1/EDG1激活相关的内皮细胞层功能的改善相结合，使得这类化合物在治疗不受控制的炎症性疾病和改善血管功能方面非常有用。
• [EN] NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS<br/>[FR] NOUVEAUX DERIVES DU THIOPHENE UTILISES COMME AGENTS IMMUNOSUPRESSEURS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2006010379A1

  公开（公告）日：2006-02-02

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  该发明涉及新型噻吩衍生物，其制备以及作为药用活性化合物的用途。这些化合物特别作为免疫抑制剂。
• Novel Thiophene Derivatives
  申请人：Bolli Martin

  公开号：US20080064740A1

  公开（公告）日：2008-03-13

  The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

  本发明涉及新型噻吩衍生物、其制备方法以及作为药物活性化合物的用途。所述化合物特别作为免疫抑制剂。